Pharmaceutical company focused on diabetes, obesity, oncology, immunology, and neuroscience.
Data window 5D · 3 evidence documents
LLY sentiment strengthened over the last five sessions as source language around glp-1 demand, capacity expansion, and pipeline breadth improved.
The prior baseline was less differentiated, with lower topic momentum and fewer high-importance documents tied to glp-1.
GLP-1 demand, capacity expansion, and pipeline breadth
Manufacturing scale-up and payer access discussion
GLP-1, GLP-1 capacity and demand durability
Source agreement is generally aligned with price and topic momentum.
Topic-level sentiment, momentum, intensity percentile, risk level, source count, summary, and top source.
Select any source to inspect summary, excerpt, metadata, reliability, and NLP contribution.
Narrative changes around earnings, filings, regulatory events, product updates, and market catalysts.
Source-backed language around obesity treatment demand and capacity additions remained strongly positive.
Sector average sentiment 59 · SPY average sentiment 60
| Ticker | Sentiment | 5D change | Risk | News volume | Primary topic | Regulatory risk | Confidence |
|---|---|---|---|---|---|---|---|
| UNH | 37 | -9.6 pts | Risk 79 | 86 | Regulatory scrutiny | Baseline | High confidence · 82 |
| LLY | 86 | +8.6 pts | Risk 39 | 84 | GLP-1 | Baseline | High confidence · 90 |
| JNJ | 55 | -1.1 pts | Risk 60 | 58 | Regulatory scrutiny | Baseline | Medium confidence · 78 |
Ticker-specific alert feed with source count, driver, suggested workflow, status, and confidence.
GLP-1 topic momentum reached the 97th percentile with broad source support from transcripts, news, and company updates.
Driver: GLP-1 capacity and demand durability. Threshold: Topic momentum > 90. Workflow: Open theme monitor and inspect health-care read-throughs.